Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
101.34 USD | +2.63% | +2.11% | -32.54% |
Sales 2023 * | 4.24B 4.56B | Sales 2024 * | 4.01B 4.31B | Capitalization | 22.32B 24.02B |
---|---|---|---|---|---|
Net income 2023 * | 1.06B 1.14B | Net income 2024 * | 625M 673M | EV / Sales 2023 * | 1,16x |
Net cash position 2023 * | 17.4B 18.73B | Net cash position 2024 * | 18.36B 19.76B | EV / Sales 2024 * | 0,99x |
P/E ratio 2023 * | 21,5x | P/E ratio 2024 * | 39,2x | Employees | 5,700 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 86.48% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +2.63% | ||
1 week | +2.11% | ||
Current month | +0.93% | ||
1 month | +1.63% | ||
3 months | -15.59% | ||
6 months | -7.75% | ||
Current year | -32.54% |
1 week
94.70
102.51

1 month
94.70
103.41

Current year
88.00
156.28

1 year
88.00
188.99

3 years
80.55
464.00

5 years
12.53
464.00

10 years
12.53
464.00

Managers | Title | Age | Since |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 2008 |
Özlem Türeci
FOU | Founder | 56 | 2008 |
Jens Holstein
DFI | Director of Finance/CFO | 59 | 2021 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 2008 | |
Helmut Jeggle
CHM | Chairman | 53 | 2008 |
Director/Board Member | 62 | 2017 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.25% | 12 M€ | -19.99% | ||
4.80% | 3 M€ | -15.14% | - | |
4.80% | 104 M€ | -16.57% | ||
4.58% | 5 M€ | -16.24% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-06 | 101.34 | +2.63% | 810,326 |
23-12-05 | 98.74 | -1.17% | 800,594 |
23-12-04 | 99.91 | +0.51% | 823,208 |
23-12-01 | 99.4 | -1.01% | 802,924 |
23-11-30 | 100.41 | +1.17% | 658,831 |
Delayed Quote Nasdaq, December 06, 2023 at 04:00 pm EST
More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
2024-03-19
- Q4 2023 Earnings Call
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
93.89EUR
Average target price
123.77EUR
Spread / Average Target
+31.82%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.54% | 24 090 M $ | |
+22.40% | 91 081 M $ | |
+15.84% | 88 879 M $ | |
-5.98% | 31 581 M $ | |
+22.60% | 27 228 M $ | |
-24.35% | 21 026 M $ | |
-17.26% | 18 954 M $ | |
+0.03% | 11 738 M $ | |
+22.68% | 11 133 M $ | |
-32.57% | 8 174 M $ |